EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Diagnostic utility of 11 C‐methionine PET/CT in primary hyperparathyroidism in a UK cohort: A single‐centre experience and literature review

Kevin A Huynh iD, James MacFarlane, Christine Newman, Daniel Gillett, Tilak Das, Daniel Scoffings, Heok K Cheow, Penelope Moyle, Olympia Koulouri, Ines Harper, Luigi Aloj, Iosif A Mendichovszky und 13 weitere

Clinical Endocrinology · 2023

DOI: 10.1111/cen.14933 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Kevin A Huynh und 24 weiteren Autor:innen. Beteiligte Einrichtung: Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge an…. Hauptthemen laut MEDLINE: Hyperparathyroidism, Primary, Parathyroid Neoplasms, Adenoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Primary hyperparathyroidism is a common endocrine disorder, with 80% of all cases usually caused by one single hyperfunctioning parathyroid adenoma. Conventional imaging modalities for the diagnostic work‐up of primary hyperparathyroidism (PHPT) include ultrasound of the neck, 99mTc‐sestamibi scintigraphy, and four‐dimensional computed tomography (4D‐CT). However, the role of other imaging modalities, such as 11C‐methionine PET/CT, in the care pathway for PHPT is currently unclear. Here, we report our experience of the diagnostic utility of 11C‐methionine PET/CT in a single‐center patient cohort ( n = 45).

Design

Retrospective single‐center cohort study. Patients and Measurements The data of eligible patients that underwent 11C‐methionine PET/CT between 2014 and 2022 at Addenbrooke's Hospital (Cambridge, UK) were collected and analyzed. The clinical utility of imaging modalities was determined by comparing the imaging result with histopathological and biochemical outcomes following surgery.

Results

In patients with persistent primary hyperparathyroidism following previous surgery, 11C‐methionine PET/CT identified a candidate lesion in 6 of 10 patients (60.0%), and histologically confirmed in 5 (50.0%). 11C‐methionine PET/CT also correctly identified a parathyroid adenoma in 9 out of 12 patients (75.0%) that failed to be localized on other imaging modalities. 11C‐methionine PET/CT had a sensitivity of 70.0% (95% CI 55.8 – 84.2%) for the detection of parathyroid adenomas.

Conclusions

This study highlights a diagnostic role for 11C‐methionine PET/CT in patients that have undergone unsuccessful prior surgery or have equivocal or negative prior imaging results, aiding localization and a targeted surgical approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperparathyroidism, PrimaryParathyroid NeoplasmsAdenomaHumansPositron Emission Tomography Computed TomographyRetrospective StudiesCohort StudiesMethionineTechnetium Tc 99m SestamibiRacemethionineUnited KingdomParathyroid GlandsCarbon Radioisotopes

Stichwörter der Autor:innen

11C-methionine PET/CTmolecular/functional imagingparathyroid adenomaprimary hyperparathyroidism

Substanzen

MethionineTechnetium Tc 99m SestamibiRacemethionineCarbon-11Carbon Radioisotopescarbon-11 methionine

Autor:innen und Institutionen

  • Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research…
  • Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Department of Radiology, University of Cambridge, Cambridge, UK.
  • Royal Wolverhampton NHS Trust, Wolverhampton, UK.
  • Department of Endocrinology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Department of ENT/Head and Neck Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

ORCID-Profile: Kevin A Huynh, Ruth T Casey

Förderung

  • Department of Health

Zitieren

APA

Huynh, K. A., MacFarlane, J., Newman, C., Gillett, D., Das, T., Scoffings, D., Cheow, H. K., Moyle, P., Koulouri, O., Harper, I., Aloj, L., Mendichovszky, I. A., Inchiappa, D., Buch, H. N., Chung, T. T., Simpson, H. L., Powlson, A. S., Challis, B. G., Bashari, W. A., …, & Casey, R. T. (2023). Diagnostic utility of 11 C‐methionine PET/CT in primary hyperparathyroidism in a UK cohort: A single‐centre experience and literature review. Clinical Endocrinology. https://doi.org/10.1111/cen.14933

Vancouver

Huynh KA, MacFarlane J, Newman C, Gillett D, Das T, Scoffings D, et al. Diagnostic utility of 11 C‐methionine PET/CT in primary hyperparathyroidism in a UK cohort: A single‐centre experience and literature review. Clinical Endocrinology. 2023. doi:10.1111/cen.14933

BibTeX
@article{Huynh2023,
  author = {Huynh, Kevin A and MacFarlane, James and Newman, Christine and Gillett, Daniel and Das, Tilak and Scoffings, Daniel and Cheow, Heok K and Moyle, Penelope and Koulouri, Olympia and Harper, Ines and Aloj, Luigi and Mendichovszky, Iosif A and Inchiappa, Danilo and Buch, Harit N and Chung, Teng-Teng and Simpson, Helen L and Powlson, Andrew S and Challis, Ben G and Bashari, Waiel A and Stokes, Victoria J and Masterson, Liam and Jani, Piyush and Fish, Brian and Gurnell, Mark and Casey, Ruth T},
  title = {Diagnostic utility of 11 C‐methionine PET/CT in primary hyperparathyroidism in a UK cohort: A single‐centre experience and literature review},
  journal = {Clinical Endocrinology},
  year = {2023},
  doi = {10.1111/cen.14933}
}
Kostenlos starten →